Education
About Us
Working with TipRanks
Follow Us
Karyopharm Therapeutics (KPTI)
NASDAQ:KPTI
KPTI Stock Chart & Stats
$8.77
-$0.04(-5.28%)
At close: 4:00 PM EST
$8.77
-$0.04(-5.28%)
Day’s Range― - ―
52-Week Range$3.51 - $10.99
Previous CloseN/A
Volume220.82K
Average Volume (3M)228.24K
Market Cap
$160.88M
Enterprise Value$247.94M
Total Cash (Recent Filing)$63.74M
Total Debt (Recent Filing)$233.61M
Price to Earnings (P/E)―
Beta1.23
Next Earnings
Apr 30, 2026EPS Estimate
-1.3Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-5.71
Shares Outstanding18,343,967
10 Day Avg. Volume494,784
30 Day Avg. Volume228,238
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)-0.27
Price to Sales (P/S)0.55
P/FCF Ratio-1.07
Enterprise Value/Market Cap1.54
Enterprise Value/Revenue1.70
Enterprise Value/Gross Profit1.77
Enterprise Value/Ebitda-3.15
Forecast
1Y Price Target
$19.50Price Target Upside122.35% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)-4.85
Revenue Forecast (FY)$139.15M
Bulls Say, Bears Say
Bulls Say
Commercial Adoption PotentialHigh overlap between the targeted myelofibrosis patient population and existing community accounts, together with strong physician intent to adopt the combination therapy, suggests potential for rapid commercial uptake if approved.
Early Clinical Data ConsistencyConsistent early-stage results showing larger spleen volume reductions and greater symptom improvements for the selinexor and ruxolitinib combination versus ruxolitinib alone reduce clinical risk and increase the probability of a successful Phase 3 outcome.
Phase 3 Trial ReadoutPositive top-line Phase 3 SENTRY results for the Xpovio plus Jakafi combination would validate the late-stage program and support analyst Buy ratings, driving meaningful revaluation of the stock.
Bears Say
Clinical, Regulatory And Financing RisksMaterial risks such as negative clinical data, slower-than-expected trial timelines, failure to obtain regulatory approvals, lower market uptake, and potential dilution from future financing could substantially weaken the stock.
Co-primary Endpoint RiskThe trial requires meeting both spleen volume reduction and symptom improvement co-primary endpoints, creating a binary outcome that could dramatically swing the stock depending on results.
Legacy Franchise UnderperformanceUnderperformance of the existing multiple myeloma franchise due to limited durability and tolerability concerns has pressured valuation and could limit upside if new programs falter.
Karyopharm Therapeutics News
KPTI FAQ
What was Karyopharm Therapeutics’s price range in the past 12 months?
Karyopharm Therapeutics lowest stock price was $3.51 and its highest was $10.99 in the past 12 months.
What is Karyopharm Therapeutics’s market cap?
Karyopharm Therapeutics’s market cap is $160.88M.
When is Karyopharm Therapeutics’s upcoming earnings report date?
Karyopharm Therapeutics’s upcoming earnings report date is Apr 30, 2026 which is in 52 days.
How were Karyopharm Therapeutics’s earnings last quarter?
Karyopharm Therapeutics released its earnings results on Feb 12, 2026. The company reported -$5.71 earnings per share for the quarter, missing the consensus estimate of -$1.994 by -$3.716.
Is Karyopharm Therapeutics overvalued?
According to Wall Street analysts Karyopharm Therapeutics’s price is currently Undervalued.
Does Karyopharm Therapeutics pay dividends?
Karyopharm Therapeutics does not currently pay dividends.
What is Karyopharm Therapeutics’s EPS estimate?
Karyopharm Therapeutics’s EPS estimate is -1.3.
How many shares outstanding does Karyopharm Therapeutics have?
Karyopharm Therapeutics has 18,343,967 shares outstanding.
What happened to Karyopharm Therapeutics’s price movement after its last earnings report?
Karyopharm Therapeutics reported an EPS of -$5.71 in its last earnings report, missing expectations of -$1.994. Following the earnings report the stock price went up 21.303%.
Which hedge fund is a major shareholder of Karyopharm Therapeutics?
Currently, no hedge funds are holding shares in KPTI
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Karyopharm Therapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$19.50 (122.35% Upside)
$19.50 (122.35% Upside)
Hedge Fund Trend
Decreased
By 8.9K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▼ 0.9%
Last 30 Days ▲ 10.2%
Last 30 Days ▲ 10.2%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-53.70%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-50.99%
Trailing 12-Months
Company Description
Karyopharm Therapeutics
Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases. The company discovers, develops, and commercializes novel and Selective Inhibitor of Nuclear Export (SINE) compounds function by binding with and inhibiting the nuclear export protein XPO1. Its lead compound, include XPOVIO in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma, in combination with dexamethasone for the treatment of adult patients with heavily pretreated multiple myeloma, and for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma. The company has license agreement with Menarini Group to develop and commercialize NEXPOVIO for human oncology indications in Europe, including the United Kingdom; Latin America; and other countries. Its oral SINE compounds also designed to force nuclear accumulation in the levels of multiple tumor suppressor and growth regulatory proteins. The company was incorporated in 2008 and is headquartered in Newton, Massachusetts.
KPTI Company Deck
KPTI Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call presents a mixed but measured outlook: strong near‑term clinical catalysts (SENTRY in March and EXPORT EC042 mid‑2026), encouraging early efficacy and tolerability data, modest product revenue growth and demonstrated cost discipline. Offsetting these positives are a constrained cash runway (into Q2 2026), large GAAP losses driven by debt‑related and noncash items, elevated interest expense, and dependence on binary Phase III readouts to drive future value. Overall, the balance of significant upside potential from pending pivotal data against material near‑term financial constraints yields a neutral stance.View all KPTI earnings summariesKPTI Stock 12 Month Forecast
Average Price Target
$19.50
▲(122.35% Upside)
Technical Analysis
Actinium Pharmaceuticals
―
Bioxcel Therapeutics
―
Lantern Pharma
―
Century Therapeutics
―
Medicus Pharma Ltd
―
Ownership Overview
4.46% Insiders
17.61% Mutual Funds
10.57% Other Institutional Investors
64.67% Public Companies and
Individual Investors